01 — The Text
What.
- Reauthorizes two federal programs through 2031 that help patients get bone marrow and umbilical cord blood transplants from unrelated donors.
- Removes the 150,000-unit inventory goal for cord blood banks; lets HRSA set targets based on actual clinical demand.
- Requires cord blood banks to meet FDA standards and current industry quality requirements to participate in the federal program.
02 — The Stakes
So what?
- Patients needing blood-forming cell transplants (for leukemia, lymphoma, sickle cell disease) depend on these donor networks to find matches.
- Hospitals and transplant centers get clearer quality standards and flexible inventory planning instead of a fixed numerical target.
- Cord blood banks must upgrade to stricter standards or lose federal contracts—raising compliance costs but improving product safety.
03 — The Path
Now what?
- House passed it July 20; now in Senate awaiting committee review or floor action. No timeline yet for Senate vote.
- Contact your senator to track their position, especially if you have transplant patients in your family or community.
Legislative History
Actions.
- Jul 21, 2026 — Received in the Senate. Read twice. Placed on Senate Legislative Calendar under General Orders. Calendar No. 464.
- Jul 20, 2026 — Motion to reconsider laid on the table Agreed to without objection.
- Jul 20, 2026 — On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H4642)
- Jul 20, 2026 — Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H4642)
- Jul 20, 2026 — DEBATE - The House proceeded with forty minutes of debate on H.R. 5160.
- Jul 20, 2026 — Considered under suspension of the rules. (consideration: CR H4642-4643)
- Jul 20, 2026 — Mr. Guthrie moved to suspend the rules and pass the bill, as amended.
- Jul 2, 2026 — Placed on the Union Calendar, Calendar No. 629.